Pharma — Marts 2023
-
Dagens aviser med Novo Nordisk, KBHL og Ørsted https://www.proinvestor.com/investornyt/952022/torsdagens-aviser-med-novo-nordisk-kbhl-og-orsted
-
Pfizer Stock (NYSE:PFE): Exceptional Value Near 52-Week Lows
https://www.proinvestor.com/investornyt/956590/pfizer-stock-nysepfe-exceptional-value-near-52-week-lows -
Could This Be Merck's Next Blockbuster
Drug? https://www.proinvestor.com/investornyt/956634/could-this-be-mercks-next-blockbuster-drug -
Ready to Buy the Dip? Johnson & Johnson Stock Is a Smart Buy
https://www.proinvestor.com/investornyt/956635/ready-to-buy-the-dip-johnson-amp-johnson-stock-is-a-smart-buy -
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing https://www.proinvestor.com/investornyt/956850/novartis-sma-drug-zolgensma-long-term-data-shows-sustained-durability-up-to-75-years-post-dosing
-
Roche : New Data For Evrysdi Reinforce Long-Term Efficacy And Safety Profile In Types 2 And 3 SMA https://www.proinvestor.com/investornyt/956868/roche-new-data-for-evrysdi-reinforce-long-term-efficacy-and-safety-profile-in-types-2-and-3-sma
-
Is Roche a Buy Now? https://www.proinvestor.com/investornyt/956954/is-roche-a-buy-now
-
Sanofi : EU Approves Dupixent To Treat Severe Atopic Dermatitis In Children https://www.proinvestor.com/investornyt/957400/sanofi-eu-approves-dupixent-to-treat-severe-atopic-dermatitis-in-children
-
Sanofi og Regeneron stiger 6-7%.Forsøg viser god virkning af Dupixent mod KOL. https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-demonstrates-potential-become-first-biologic
-
Novartis stiger oven på lovende kræftstudie
27.3.2023 09.10 • MarketWire •
Novartis har fået en god start på børshandlen mandag, efter at medicinalkoncernen har præsenteret lovende resultater fra et studie med kræftmidlet Kisqali.Det rapporterer Bloomberg News.
Kisqali er i forvejen godkendt til behandling af brystkræft, og det nye studie viser, at midlet antyder, at det også reducerer risikoen for, at brystkræften vender tilbage.
Aktien i Novartis stiger fra åbningen med omkring 5 pct.
.\
-
Nå, linket lader sig ikke copypaste https://investors.biontech.de/node/14871/pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind